Scholl/Amopé decline holds back RB in 2016

16 February 2017 - Deborah Wilkes

Archived

A "double-digit decline" for Scholl/Amopé footcare products held back sales growth at RB's Health division in 2016. The UK-based firm said Scholl/Amopé would be supported by new product initiatives during the first half of 2017, as would the Nurofen and KY brands.

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: